[3]
Bioletto F, Lopez C, Bollati M, Arata S, Procopio M, Ponzetto F, Beccuti G, Mengozzi G, Ghigo E, Maccario M, Parasiliti-Caprino M. Predictive performance of aldosterone-to-renin ratio in the diagnosis of primary aldosteronism in patients with resistant hypertension. Frontiers in endocrinology. 2023:14():1145186. doi: 10.3389/fendo.2023.1145186. Epub 2023 May 8
[PubMed PMID: 37223051]
[4]
Ananda RA, Gwini SM, Long KM, Lai JH, Chen G, Russell GM, Stowasser M, Fuller PJ, Yang J. Diagnostic Delay and Disease Burden in Primary Aldosteronism: An International Patient Survey. Hypertension (Dallas, Tex. : 1979). 2024 Feb:81(2):348-360. doi: 10.1161/HYPERTENSIONAHA.123.21965. Epub 2023 Dec 14
[PubMed PMID: 38095087]
Level 3 (low-level) evidence
[5]
Kim V, Shi J, An J, Bhandari S, Brettler JW, Kanter MH, Sim JJ. Hyperaldosteronism Screening and Findings From a Large Diverse Population With Resistant Hypertension Within an Integrated Health System. The Permanente journal. 2023 Nov 27:():1-11. doi: 10.7812/TPP/23.096. Epub 2023 Nov 27
[PubMed PMID: 38009955]
[6]
Morera J, Reznik Y. MANAGEMENT OF ENDOCRINE DISEASE: The role of confirmatory tests in the diagnosis of primary aldosteronism. European journal of endocrinology. 2019 Feb 1:180(2):R45-R58. doi: 10.1530/EJE-18-0704. Epub
[PubMed PMID: 30475220]
[9]
Lee FT, Elaraj D. Evaluation and Management of Primary Hyperaldosteronism. The Surgical clinics of North America. 2019 Aug:99(4):731-745. doi: 10.1016/j.suc.2019.04.010. Epub
[PubMed PMID: 31255203]
[10]
Halperin F, Dluhy RG. Glucocorticoid-remediable aldosteronism. Endocrinology and metabolism clinics of North America. 2011 Jun:40(2):333-41, viii. doi: 10.1016/j.ecl.2011.01.012. Epub
[PubMed PMID: 21565670]
[11]
Funder JW. The genetic basis of primary aldosteronism. Current hypertension reports. 2012 Apr:14(2):120-4. doi: 10.1007/s11906-012-0255-x. Epub
[PubMed PMID: 22359160]
[12]
Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Åkerström G, Wang W, Carling T, Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science (New York, N.Y.). 2011 Feb 11:331(6018):768-72. doi: 10.1126/science.1198785. Epub
[PubMed PMID: 21311022]
[13]
Quack I, Vonend O, Rump LC. Familial hyperaldosteronism I-III. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2010 Jun:42(6):424-8. doi: 10.1055/s-0029-1246187. Epub 2010 Feb 3
[PubMed PMID: 20131203]
[14]
Dutta RK, Söderkvist P, Gimm O. Genetics of primary hyperaldosteronism. Endocrine-related cancer. 2016 Oct:23(10):R437-54. doi: 10.1530/ERC-16-0055. Epub 2016 Aug 2
[PubMed PMID: 27485459]
[17]
Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Papadopoulou-Marketou N, Vaidya A, Dluhy R, Chrousos GP. Hyperaldosteronism. Endotext. 2000:():
[PubMed PMID: 25905293]
[18]
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2016 May:101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2
[PubMed PMID: 26934393]
Level 3 (low-level) evidence
[19]
Prejbisz A, Warchoł-Celińska E, Lenders JW, Januszewicz A. Cardiovascular Risk in Primary Hyperaldosteronism. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2015 Dec:47(13):973-80. doi: 10.1055/s-0035-1565124. Epub 2015 Nov 17
[PubMed PMID: 26575306]
[20]
Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Annals of internal medicine. 2020 Jul 7:173(1):10-20. doi: 10.7326/M20-0065. Epub 2020 May 26
[PubMed PMID: 32449886]
Level 2 (mid-level) evidence
[21]
Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. Journal of internal medicine. 2019 Feb:285(2):126-148. doi: 10.1111/joim.12831. Epub 2018 Sep 25
[PubMed PMID: 30255616]
Level 3 (low-level) evidence
[22]
Cohen JB, Cohen DL, Herman DS, Leppert JT, Byrd JB, Bhalla V. Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study. Annals of internal medicine. 2021 Mar:174(3):289-297. doi: 10.7326/M20-4873. Epub 2020 Dec 29
[PubMed PMID: 33370170]
Level 2 (mid-level) evidence
[23]
Faconti L, Kulkarni S, Delles C, Kapil V, Lewis P, Glover M, MacDonald TM, Wilkinson IB. Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society. Journal of human hypertension. 2024 Jan:38(1):8-18. doi: 10.1038/s41371-023-00875-1. Epub 2023 Nov 14
[PubMed PMID: 37964158]
[24]
Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. Journal of human hypertension. 2003 May:17(5):349-52
[PubMed PMID: 12756408]
[25]
Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension (Dallas, Tex. : 1979). 2002 Dec:40(6):892-6
[PubMed PMID: 12468575]
[26]
Jaffe G, Gray Z, Krishnan G, Stedman M, Zheng Y, Han J, Chertow GM, Leppert JT, Bhalla V. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study. Hypertension (Dallas, Tex. : 1979). 2020 Mar:75(3):650-659. doi: 10.1161/HYPERTENSIONAHA.119.14359. Epub 2020 Feb 3
[PubMed PMID: 32008436]
[27]
Käyser SC, Deinum J, de Grauw WJ, Schalk BW, Bor HJ, Lenders JW, Schermer TR, Biermans MC. Prevalence of primary aldosteronism in primary care: a cross-sectional study. The British journal of general practice : the journal of the Royal College of General Practitioners. 2018 Feb:68(667):e114-e122. doi: 10.3399/bjgp18X694589. Epub 2018 Jan 15
[PubMed PMID: 29335324]
Level 2 (mid-level) evidence
[28]
Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. The Journal of clinical endocrinology and metabolism. 2004 Mar:89(3):1045-50
[PubMed PMID: 15001583]
[29]
Moustaki M, Paschou SA, Vakali EC, Vryonidou A. Secondary diabetes mellitus due to primary aldosteronism. Endocrine. 2023 Jan:79(1):17-30. doi: 10.1007/s12020-022-03168-8. Epub 2022 Aug 24
[PubMed PMID: 36001240]
[30]
Luther JM. Effects of aldosterone on insulin sensitivity and secretion. Steroids. 2014 Dec:91():54-60. doi: 10.1016/j.steroids.2014.08.016. Epub 2014 Sep 4
[PubMed PMID: 25194457]
[31]
Adler GK, Murray GR, Turcu AF, Nian H, Yu C, Solorzano CC, Manning R, Peng D, Luther JM. Primary Aldosteronism Decreases Insulin Secretion and Increases Insulin Clearance in Humans. Hypertension (Dallas, Tex. : 1979). 2020 May:75(5):1251-1259. doi: 10.1161/HYPERTENSIONAHA.119.13922. Epub 2020 Mar 16
[PubMed PMID: 32172621]
[32]
Gioco F, Seccia TM, Gomez-Sanchez EP, Rossi GP, Gomez-Sanchez CE. Adrenal histopathology in primary aldosteronism: is it time for a change? Hypertension (Dallas, Tex. : 1979). 2015 Oct:66(4):724-30. doi: 10.1161/HYPERTENSIONAHA.115.05873. Epub 2015 Aug 3
[PubMed PMID: 26238443]
[35]
Conn JW, Cohen EL, Rovner DR. Landmark article Oct 19, 1964: Suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. By Jerome W. Conn, Edwin L. Cohen and David R. Rovner. JAMA. 1985 Jan 25:253(4):558-66
[PubMed PMID: 3881606]
[36]
Vilela LAP, Almeida MQ. Diagnosis and management of primary aldosteronism. Archives of endocrinology and metabolism. 2017 May-Jun:61(3):305-312. doi: 10.1590/2359-3997000000274. Epub
[PubMed PMID: 28699986]
[37]
Vakkalanka S, Zhao A, Samannodi M. Primary hyperaldosteronism: a case of unilateral adrenal hyperplasia with contralateral incidentaloma. BMJ case reports. 2016 Jul 14:2016():. doi: 10.1136/bcr-2016-216209. Epub 2016 Jul 14
[PubMed PMID: 27417992]
Level 3 (low-level) evidence
[38]
Turner JM, Dmitriev M. Secondary Hypertension Overview and Workup for the Primary Care Physician. The Medical clinics of North America. 2023 Jul:107(4):739-747. doi: 10.1016/j.mcna.2023.03.010. Epub 2023 Apr 18
[PubMed PMID: 37258011]
Level 3 (low-level) evidence
[39]
Stowasser M, Gordon RD. The aldosterone-renin ratio and primary aldosteronism. Mayo Clinic proceedings. 2002 Feb:77(2):202-3
[PubMed PMID: 11838659]
[40]
Veldhuizen GP, Alnazer RM, Kroon AA, de Leeuw PW. Variability of aldosterone, renin and the aldosterone-to-renin ratio in hypertensive patients without primary aldosteronism. Journal of hypertension. 2022 Nov 1:40(11):2256-2262. doi: 10.1097/HJH.0000000000003257. Epub 2022 Aug 8
[PubMed PMID: 35950999]
[41]
Gordon RD, Wolfe LK, Island DP, Liddle GW. A diurnal rhythm in plasma renin activity in man. The Journal of clinical investigation. 1966 Oct:45(10):1587-92
[PubMed PMID: 4288714]
[42]
Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, Kong AP. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. The Journal of clinical endocrinology and metabolism. 2005 Jan:90(1):72-8
[PubMed PMID: 15483077]
[43]
Ahmed AH, Calvird M, Gordon RD, Taylor PJ, Ward G, Pimenta E, Young R, Stowasser M. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. The Journal of clinical endocrinology and metabolism. 2011 Apr:96(4):1039-45. doi: 10.1210/jc.2010-2603. Epub 2011 Feb 2
[PubMed PMID: 21289246]
[44]
Ahmed AH, Gordon RD, Ward G, Wolley M, McWhinney BC, Ungerer JP, Stowasser M. Effect of Combined Hormonal Replacement Therapy on the Aldosterone/Renin Ratio in Postmenopausal Women. The Journal of clinical endocrinology and metabolism. 2017 Jul 1:102(7):2329-2334. doi: 10.1210/jc.2016-3851. Epub
[PubMed PMID: 28379474]
[45]
Grasso M, Boscaro M, Scaroni C, Ceccato F. Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension. 2018 Dec:25(4):345-354. doi: 10.1007/s40292-018-0288-6. Epub 2018 Nov 10
[PubMed PMID: 30415425]
[46]
Vaidya A, Mulatero P, Baudrand R, Adler GK. The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment. Endocrine reviews. 2018 Dec 1:39(6):1057-1088. doi: 10.1210/er.2018-00139. Epub
[PubMed PMID: 30124805]
[47]
Seccia TM, Caroccia B, Gomez-Sanchez EP, Gomez-Sanchez CE, Rossi GP. The Biology of Normal Zona Glomerulosa and Aldosterone-Producing Adenoma: Pathological Implications. Endocrine reviews. 2018 Dec 1:39(6):1029-1056. doi: 10.1210/er.2018-00060. Epub
[PubMed PMID: 30007283]
[48]
Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension (Dallas, Tex. : 1979). 2003 Aug:42(2):161-5
[PubMed PMID: 12796282]
[49]
Baguet JP, Steichen O, Mounier-Véhier C, Gosse P. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA? Annales d'endocrinologie. 2016 Jul:77(3):187-91. doi: 10.1016/j.ando.2016.01.006. Epub 2016 Apr 15
[PubMed PMID: 27087531]
Level 3 (low-level) evidence
[50]
Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clinical chemistry. 2005 Feb:51(2):386-94
[PubMed PMID: 15681560]
[51]
Kassirer JP, London AM, Goldman DM, Schwartz WB. On the pathogenesis of metabolic alkalosis in hyperaldosteronism. The American journal of medicine. 1970 Sep:49(3):306-15
[PubMed PMID: 5455562]
[52]
Blanchard A. Pathophysiologic approach in genetic hypokalemia: An update. Annales d'endocrinologie. 2023 Apr:84(2):298-307. doi: 10.1016/j.ando.2022.11.005. Epub 2023 Jan 10
[PubMed PMID: 36639120]
[53]
Muto S, Asano Y, Okazaki H, Kano S. Renal potassium wasting in distal renal tubular acidosis: role of aldosterone. Internal medicine (Tokyo, Japan). 1992 Aug:31(8):1047-51
[PubMed PMID: 1335804]
[54]
Kaneko H, Umakoshi H, Ishihara Y, Nanba K, Tsuiki M, Kusakabe T, Satoh-Asahara N, Yasoda A, Tagami T. Reassessment of Urinary Aldosterone Measurement After Saline Infusion in Primary Aldosteronism. Journal of the Endocrine Society. 2020 Sep 1:4(9):bvaa100. doi: 10.1210/jendso/bvaa100. Epub 2020 Jul 22
[PubMed PMID: 32803096]
[55]
Wu CH, Yang YW, Hu YH, Tsai YC, Kuo KL, Lin YH, Hung SC, Wu VC, Wu KD, Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group. Comparison of 24-h urinary aldosterone level and random urinary aldosterone-to-creatinine ratio in the diagnosis of primary aldosteronism. PloS one. 2013:8(6):e67417. doi: 10.1371/journal.pone.0067417. Epub 2013 Jun 28
[PubMed PMID: 23840695]
[56]
Wu S, Yang J, Hu J, Song Y, He W, Yang S, Luo R, Li Q. Confirmatory tests for the diagnosis of primary aldosteronism: A systematic review and meta-analysis. Clinical endocrinology. 2019 May:90(5):641-648. doi: 10.1111/cen.13943. Epub 2019 Feb 26
[PubMed PMID: 30721529]
Level 1 (high-level) evidence
[57]
Piaditis GP, Kaltsas GA, Androulakis II, Gouli A, Makras P, Papadogias D, Dimitriou K, Ragkou D, Markou A, Vamvakidis K, Zografos G, Chrousos G. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clinical endocrinology. 2009 Dec:71(6):772-8. doi: 10.1111/j.1365-2265.2009.03551.x. Epub 2009 Feb 18
[PubMed PMID: 19226269]
[58]
Gordon RD. Primary aldosteronism. Journal of endocrinological investigation. 1995 Jul-Aug:18(7):495-511
[PubMed PMID: 9221268]
[59]
Gordon RD, Stowasser M, Klemm SA, Tunny TJ. Primary aldosteronism--some genetic, morphological, and biochemical aspects of subtypes. Steroids. 1995 Jan:60(1):35-41
[PubMed PMID: 7792813]
[60]
Fuller PJ. Adrenal Diagnostics: An Endocrinologist's Perspective focused on Hyperaldosteronism. The Clinical biochemist. Reviews. 2013 Nov:34(3):111-6
[PubMed PMID: 24353356]
Level 3 (low-level) evidence
[61]
Schmiemann G, Gebhardt K, Hummers-Pradier E, Egidi G. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. Journal of the American Board of Family Medicine : JABFM. 2012 Jan-Feb:25(1):98-103. doi: 10.3122/jabfm.2012.01.110099. Epub
[PubMed PMID: 22218630]
[62]
Gouli A, Kaltsas G, Tzonou A, Markou A, Androulakis II, Ragkou D, Vamvakidis K, Zografos G, Kontogeorgos G, Chrousos GP, Piaditis G. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. European journal of clinical investigation. 2011 Nov:41(11):1227-36. doi: 10.1111/j.1365-2362.2011.02531.x. Epub 2011 May 3
[PubMed PMID: 21534948]
[63]
Lucatello B, Benso A, Tabaro I, Capello E, Caprino MP, Marafetti L, Rossato D, Oleandri SE, Ghigo E, Maccario M. Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion. European journal of endocrinology. 2013 Apr:168(4):525-32. doi: 10.1530/EJE-12-0912. Epub 2013 Mar 15
[PubMed PMID: 23321497]
[64]
Markou A, Pappa T, Kaltsas G, Gouli A, Mitsakis K, Tsounas P, Prevoli A, Tsiavos V, Papanastasiou L, Zografos G, Chrousos GP, Piaditis GP. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. The Journal of clinical endocrinology and metabolism. 2013 Apr:98(4):1409-16. doi: 10.1210/jc.2012-3353. Epub 2013 Mar 7
[PubMed PMID: 23471976]
[65]
Papanastasiou L, Markou A, Pappa T, Gouli A, Tsounas P, Fountoulakis S, Kounadi T, Tsiama V, Dasou A, Gryparis A, Samara C, Zografos G, Kaltsas G, Chrousos G, Piaditis G. Primary aldosteronism in hypertensive patients: clinical implications and target therapy. European journal of clinical investigation. 2014 Aug:44(8):697-706. doi: 10.1111/eci.12286. Epub
[PubMed PMID: 24909545]
[66]
Stowasser M, Klemm SA, Tunny TJ, Gordon RD. Plasma aldosterone response to ACTH in subtypes of primary aldosteronism. Clinical and experimental pharmacology & physiology. 1995 Jun-Jul:22(6-7):460-2
[PubMed PMID: 8582103]
[67]
Gleason PE, Weinberger MH, Pratt JH, Bihrle R, Dugan J, Eller D, Donohue JP. Evaluation of diagnostic tests in the differential diagnosis of primary aldosteronism: unilateral adenoma versus bilateral micronodular hyperplasia. The Journal of urology. 1993 Nov:150(5 Pt 1):1365-8
[PubMed PMID: 8411401]
[68]
Aronova A, Fahey TJ III, Zarnegar R. Management of hypertension in primary aldosteronism. World journal of cardiology. 2014 May 26:6(5):227-33. doi: 10.4330/wjc.v6.i5.227. Epub
[PubMed PMID: 24944753]
[69]
Weiner ID. Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism. Seminars in nephrology. 2013 May:33(3):265-76. doi: 10.1016/j.semnephrol.2013.04.007. Epub
[PubMed PMID: 23953804]
[70]
Harvey AM. Hyperaldosteronism: diagnosis, lateralization, and treatment. The Surgical clinics of North America. 2014 Jun:94(3):643-56. doi: 10.1016/j.suc.2014.02.007. Epub 2014 Apr 24
[PubMed PMID: 24857581]
[71]
Quencer KB. Adrenal vein sampling: technique and protocol, a systematic review. CVIR endovascular. 2021 Apr 1:4(1):38. doi: 10.1186/s42155-021-00220-y. Epub 2021 Apr 1
[PubMed PMID: 33939038]
Level 1 (high-level) evidence
[72]
Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, Satoh F, Young WF Jr. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension (Dallas, Tex. : 1979). 2014 Jan:63(1):151-60. doi: 10.1161/HYPERTENSIONAHA.113.02097. Epub 2013 Nov 11
[PubMed PMID: 24218436]
Level 3 (low-level) evidence
[73]
Pasternak JD, Epelboym I, Seiser N, Wingo M, Herman M, Cowan V, Gosnell JE, Shen WT, Kerlan RK Jr, Lee JA, Duh QY, Suh I. Diagnostic utility of data from adrenal venous sampling for primary aldosteronism despite failed cannulation of the right adrenal vein. Surgery. 2016 Jan:159(1):267-73. doi: 10.1016/j.surg.2015.06.048. Epub 2015 Oct 2
[PubMed PMID: 26435431]
[74]
Lin L, Zhou L, Guo Y, Liu Z, Chen T, Liu Z, Wang K, Li J, Zhu Y, Ren Y. Can incomplete adrenal venous sampling data be used in predicting the subtype of primary aldosteronism? Annales d'endocrinologie. 2019 Nov:80(5-6):301-307. doi: 10.1016/j.ando.2019.10.001. Epub 2019 Oct 18
[PubMed PMID: 31722788]
[75]
Burrello J, Burrello A, Pieroni J, Sconfienza E, Forestiero V, Amongero M, Rossato D, Veglio F, Williams TA, Monticone S, Mulatero P. Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful. European journal of endocrinology. 2020 Dec:183(6):657-667. doi: 10.1530/EJE-20-0656. Epub
[PubMed PMID: 33112264]
[76]
Yang YH, Chang YL, Lee BC, Lu CC, Wang WT, Hu YH, Liu HW, Lin YH, Chang CC, Wu WC, Tseng FY, Lin YH, Wu VC, Hwu CM. Strategies for subtyping primary aldosteronism. Journal of the Formosan Medical Association = Taiwan yi zhi. 2023 May 16:():. pii: S0929-6646(23)00155-9. doi: 10.1016/j.jfma.2023.05.004. Epub 2023 May 16
[PubMed PMID: 37202237]
[77]
Di Martino M, García Sanz I, Muñoz de Nova JL, Marín Campos C, Martínez Martín M, Domínguez Gadea L. NP-59 test for preoperative localization of primary hyperaldosteronism. Langenbeck's archives of surgery. 2017 Mar:402(2):303-308. doi: 10.1007/s00423-017-1561-1. Epub 2017 Feb 21
[PubMed PMID: 28224279]
[78]
Sato T, Matsutomo N, Yamamoto T, Fukami M, Kono T. Evaluation of standardized uptake value on (131)I-6β-iodomethyl-19-norcholesterol scintigraphy for diagnosis of primary aldosteronism and correspondence with adrenal venous sampling. Annals of nuclear medicine. 2023 Feb:37(2):89-98. doi: 10.1007/s12149-022-01805-w. Epub 2022 Nov 15
[PubMed PMID: 36380175]
Level 3 (low-level) evidence
[79]
Spyridonidis TJ, Apostolopoulos DJ. Is there a role for Nuclear Medicine in diagnosis and management of patients with primary aldosteronism? Hellenic journal of nuclear medicine. 2013 May-Aug:16(2):134-9
[PubMed PMID: 23865085]
[80]
O' Doherty J, O' Doherty S, Robins EG, Reilhac A. Parametric mapping for 11C-metomidate PET-computed tomography imaging in the study of primary aldosteronism. Nuclear medicine communications. 2021 Aug 17:():. doi: 10.1097/MNM.0000000000001477. Epub 2021 Aug 17
[PubMed PMID: 34406144]
[81]
Puar TH, Khoo CM, Tan CJ, Tong AKT, Tan MCS, Teo AE, Ng KS, Wong KM, Reilhac A, O'Doherty J, Gomez-Sanchez CE, Kek PC, Yee S, Tan AWK, Chuah MB, Lee DHM, Wang KW, Zheng CQ, Shi L, Robins EG, Foo RSY, for the PA CURE investigators. 11C-Metomidate PET-CT versus adrenal vein sampling to subtype primary aldosteronism: a prospective clinical trial. Journal of hypertension. 2022 Jun 1:40(6):1179-1188. doi: 10.1097/HJH.0000000000003132. Epub
[PubMed PMID: 35703880]
[82]
Lu CC, Chen CJ, Peng KY, Chueh JS, Chang CC, Yen RF, Wu VC, Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group. Predicting Treatment Response in Primary Aldosteronism Using 11 C-Metomidate Positron Emission Tomography. Clinical nuclear medicine. 2022 Nov 1:47(11):936-942. doi: 10.1097/RLU.0000000000004369. Epub 2022 Aug 12
[PubMed PMID: 36215396]
[83]
Wu X, Senanayake R, Goodchild E, Bashari WA, Salsbury J, Cabrera CP, Argentesi G, O'Toole SM, Matson M, Koo B, Parvanta L, Hilliard N, Kosmoliaptsis V, Marker A, Berney DM, Tan W, Foo R, Mein CA, Wozniak E, Savage E, Sahdev A, Bird N, Laycock K, Boros I, Hader S, Warnes V, Gillett D, Dawnay A, Adeyeye E, Prete A, Taylor AE, Arlt W, Bhuva AN, Aigbirhio F, Manisty C, McIntosh A, McConnachie A, Cruickshank JK, Cheow H, Gurnell M, Drake WM, Brown MJ. [(11)C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial. Nature medicine. 2023 Jan:29(1):190-202. doi: 10.1038/s41591-022-02114-5. Epub 2023 Jan 16
[PubMed PMID: 36646800]
[84]
Maurer E, Bartsch DK. [(11)C-metomidate PET-CT vs. selective adrenal vein sampling for prediction of surgical success in primary aldosteronism : Results of the prospective MATCH study]. Chirurgie (Heidelberg, Germany). 2023 Oct:94(10):877-878. doi: 10.1007/s00104-023-01957-z. Epub 2023 Sep 8
[PubMed PMID: 37682281]
[85]
Hu J, Xu T, Shen H, Song Y, Yang J, Zhang A, Ding H, Xing N, Li Z, Qiu L, Ma L, Yang Y, Feng Z, Du Z, He W, Sun Y, Cai J, Li Q, Chen Y, Yang S, Chongqing Primary Aldosteronism Study (CONPASS) Group. Accuracy of Gallium-68 Pentixafor Positron Emission Tomography-Computed Tomography for Subtyping Diagnosis of Primary Aldosteronism. JAMA network open. 2023 Feb 1:6(2):e2255609. doi: 10.1001/jamanetworkopen.2022.55609. Epub 2023 Feb 1
[PubMed PMID: 36795418]
Level 2 (mid-level) evidence
[86]
Stowasser M, Wolley M, Wu A, Gordon RD, Schewe J, Stölting G, Scholl UI. Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels. Current hypertension reports. 2019 Apr 4:21(4):31. doi: 10.1007/s11906-019-0934-y. Epub 2019 Apr 4
[PubMed PMID: 30949771]
[87]
Corssmit EPM, Dekkers OM. Screening in adrenal tumors. Current opinion in oncology. 2019 May:31(3):243-246. doi: 10.1097/CCO.0000000000000528. Epub
[PubMed PMID: 30844886]
Level 3 (low-level) evidence
[88]
Chikladze NM, Favorova OO, Chazova IE. Family hyperaldosteronism type I: a clinical case and review of literature. Terapevticheskii arkhiv. 2018 Sep 20:90(9):115-122. doi: 10.26442/terarkh2018909115-122. Epub
[PubMed PMID: 30701745]
Level 3 (low-level) evidence
[89]
Pons Fernández N, Moreno F, Morata J, Moriano A, León S, De Mingo C, Zuñiga Á, Calvo F. Familial hyperaldosteronism type III a novel case and review of literature. Reviews in endocrine & metabolic disorders. 2019 Mar:20(1):27-36. doi: 10.1007/s11154-018-9481-0. Epub
[PubMed PMID: 30569443]
Level 3 (low-level) evidence
[90]
Bruedgam D, Adolf C, Schneider H, Schwarzlmueller P, Mueller L, Handgriff L, Bidlingmaier M, Kunz S, Zimmermann P, Deniz S, Williams TA, Beuschlein F, Reincke M, Heinrich DA. Postoperative ACTH-stimulated aldosterone predicts biochemical outcome in primary aldosteronism. European journal of endocrinology. 2023 Dec 6:189(6):611-618. doi: 10.1093/ejendo/lvad159. Epub
[PubMed PMID: 38048424]
[91]
Chen ZW, Liao CW, Pan CT, Tsai CH, Chang YY, Chang CC, Lee BC, Chiu YW, Huang WC, Lai TS, Lu CC, Chueh JS, Wu VC, Hung CS, Lin YH, TAIPAI Study Group. Reversal of arterial stiffness in medically and surgically treated unilateral primary aldosteronism. Journal of hypertension. 2024 Mar 1:42(3):538-545. doi: 10.1097/HJH.0000000000003631. Epub 2023 Dec 7
[PubMed PMID: 38088428]
[92]
Veselý J. Spironolactone in the treatment of hypertension: a neglected molecule. Vnitrni lekarstvi. 2018 Fall:64(7-8):815-820
[PubMed PMID: 30441987]
[93]
Rossi GP, Mulatero P, Satoh F. 10 good reasons why adrenal vein sampling is the preferred method for referring primary aldosteronism patients for adrenalectomy. Journal of hypertension. 2019 Mar:37(3):603-611. doi: 10.1097/HJH.0000000000001939. Epub
[PubMed PMID: 30431526]
[94]
Williams TA, Reincke M. MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. European journal of endocrinology. 2018 Jul:179(1):R19-R29. doi: 10.1530/EJE-17-0990. Epub 2018 Apr 19
[PubMed PMID: 29674485]
[97]
Yang S, Wang G, Li N, Zhu Q. The outcomes of transcatheter adrenal ablation in patients with primary aldosteronism: a systematic review and meta-analysis. BMC endocrine disorders. 2023 May 8:23(1):103. doi: 10.1186/s12902-023-01356-9. Epub 2023 May 8
[PubMed PMID: 37150817]
Level 1 (high-level) evidence
[98]
Sacks BA, Sacks AC, Faintuch S. Radiofrequency ablation treatment for aldosterone-producing adenomas. Current opinion in endocrinology, diabetes, and obesity. 2017 Jun:24(3):169-173. doi: 10.1097/MED.0000000000000329. Epub
[PubMed PMID: 28248752]
Level 3 (low-level) evidence
[99]
Yang R, Xu L, Lian H, Gan W, Guo H. Retroperitoneoscopic-guided cool-tip radiofrequency ablation of adrenocortical aldosteronoma. Journal of endourology. 2014 Oct:28(10):1208-14. doi: 10.1089/end.2013.0635. Epub 2014 Aug 6
[PubMed PMID: 24935642]
[100]
Bouhanick B, Delchier MC, Lagarde S, Boulestreau R, Conil C, Gosse P, Rousseau H, Lepage B, Olivier P, Papadopoulos P, Trillaud H, Cremer A, for the ADERADHTA group. Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study. Journal of hypertension. 2021 Apr 1:39(4):759-765. doi: 10.1097/HJH.0000000000002708. Epub
[PubMed PMID: 33196558]
Level 3 (low-level) evidence
[101]
Oguro S, Ota H, Yanagaki S, Kawabata M, Kamada H, Omata K, Tezuka Y, Ono Y, Morimoto R, Satoh F, Toyama H, Tanimoto K, Konno D, Yamauchi M, Niwa Y, Miyamoto H, Mori K, Tanaka T, Ishihata H, Takase K. Transvenous Radiofrequency Catheter Ablation for an Aldosterone-Producing Tumor of the Left Adrenal Gland: A First in Human Case Report. Cardiovascular and interventional radiology. 2023 Dec:46(12):1666-1673. doi: 10.1007/s00270-023-03584-x. Epub 2023 Nov 16
[PubMed PMID: 37973663]
Level 3 (low-level) evidence
[102]
Oguro S, Morimoto R, Seiji K, Ota H, Kinoshita T, Kawabata M, Ono Y, Omata K, Tezuka Y, Satoh F, Ito S, Moriya N, Matsui S, Nishikawa T, Omura M, Nakai K, Nakatsuka S, Kurihara I, Miyashita K, Koda W, Minami T, Takeda Y, Kometani M, Oki Y, Oishi T, Ushio T, Goshima S, Takase K. Safety and feasibility of radiofrequency ablation using bipolar electrodes for aldosterone-producing adenoma: a multicentric prospective clinical study. Scientific reports. 2022 Aug 18:12(1):14090. doi: 10.1038/s41598-022-18136-5. Epub 2022 Aug 18
[PubMed PMID: 35982148]
Level 2 (mid-level) evidence
[103]
Parthasarathy HK, Ménard J, White WB, Young WF Jr, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM, MacDonald TM. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. Journal of hypertension. 2011 May:29(5):980-90. doi: 10.1097/HJH.0b013e3283455ca5. Epub
[PubMed PMID: 21451421]
Level 1 (high-level) evidence
[104]
Mai X, Kometani M, Yoneda T. Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review. International journal of molecular sciences. 2022 Nov 10:23(22):. doi: 10.3390/ijms232213821. Epub 2022 Nov 10
[PubMed PMID: 36430298]
[106]
Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs. 2004:64(3):245-75
[PubMed PMID: 14871169]
[107]
Carr MC, Prien EL Jr, Babayan RK. Triamterene nephrolithiasis: renewed attention is warranted. The Journal of urology. 1990 Dec:144(6):1339-40
[PubMed PMID: 2231920]
[110]
Funder JW. Primary Aldosteronism: The Next Five Years. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2017 Dec:49(12):977-983. doi: 10.1055/s-0043-119802. Epub 2017 Oct 24
[PubMed PMID: 29065433]
[111]
Kline GA, Prebtani APH, Leung AA, Schiffrin EL. Primary aldosteronism: a common cause of resistant hypertension. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2017 Jun 5:189(22):E773-E778. doi: 10.1503/cmaj.161486. Epub
[PubMed PMID: 28584041]
[112]
Cerny MA. Progress towards clinically useful aldosterone synthase inhibitors. Current topics in medicinal chemistry. 2013:13(12):1385-401
[PubMed PMID: 23688131]
[113]
Bernhardt R. The potential of targeting CYP11B. Expert opinion on therapeutic targets. 2016 Aug:20(8):923-34. doi: 10.1517/14728222.2016.1151873. Epub 2016 Mar 2
[PubMed PMID: 26854589]
Level 3 (low-level) evidence
[114]
Liu W, Li Z, Chu S, Ma X, Wang X, Jiang M, Bai G. Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism. Acta pharmaceutica Sinica. B. 2022 Jan:12(1):135-148. doi: 10.1016/j.apsb.2021.09.013. Epub 2021 Sep 21
[PubMed PMID: 35127376]
[115]
Zhou L, Jiang Y, Zhang C, Su T, Jiang L, Zhou W, Zhong X, Wu L, Wang W. Effects of a low-sodium diet in patients with idiopathic hyperaldosteronism: a randomized controlled trial. Frontiers in endocrinology. 2023:14():1124479. doi: 10.3389/fendo.2023.1124479. Epub 2023 Apr 19
[PubMed PMID: 37152926]
Level 1 (high-level) evidence
[118]
Al-Harbi T, Al-Shaikh A. Apparent mineralocorticoid excess syndrome: report of one family with three affected children. Journal of pediatric endocrinology & metabolism : JPEM. 2012:25(11-12):1083-8. doi: 10.1515/jpem-2012-0113. Epub
[PubMed PMID: 23329753]
[121]
Akkus G. Two Cases with 17-alpha Hydroxylase Deficiency Misdiagnosed as Primary Aldosteronism. Endocrine, metabolic & immune disorders drug targets. 2023:23(11):1449-1454. doi: 10.2174/1871530323666230407125523. Epub
[PubMed PMID: 37032508]
Level 3 (low-level) evidence
[122]
Huang H, Wang W. Molecular mechanisms of glucocorticoid resistance. European journal of clinical investigation. 2023 Feb:53(2):e13901. doi: 10.1111/eci.13901. Epub 2022 Nov 23
[PubMed PMID: 36346177]
[123]
Nicolaides NC, Charmandari E. Primary Generalized Glucocorticoid Resistance and Hypersensitivity Syndromes: A 2021 Update. International journal of molecular sciences. 2021 Oct 7:22(19):. doi: 10.3390/ijms221910839. Epub 2021 Oct 7
[PubMed PMID: 34639183]
[124]
Guia Lopes ML, Bello C, Carvalho L, Limbert C, Sequeira Duarte J. A Rare Cause of Cushing's Syndrome: an Adrenocorticotropic Hormone (ACTH)-Secreting Pheochromocytoma. Cureus. 2023 Apr:15(4):e37883. doi: 10.7759/cureus.37883. Epub 2023 Apr 20
[PubMed PMID: 37223141]
[125]
Birtolo MF, Grossrubatscher EM, Antonini S, Loli P, Mazziotti G, Lania AG, Chiodini I. Preoperative management of patients with ectopic Cushing's syndrome caused by ACTH-secreting pheochromocytoma: a case series and review of the literature. Journal of endocrinological investigation. 2023 Oct:46(10):1983-1994. doi: 10.1007/s40618-023-02105-4. Epub 2023 May 17
[PubMed PMID: 37195583]
Level 2 (mid-level) evidence
[126]
Kankoç A, Şatır Türk M, Özkan D, Sayan M, Çelik A. Typical Carcinoid Tumor Cases Causing Ectopic ACTH Syndrome: Dramatic Response to Surgery. Portuguese journal of cardiac thoracic and vascular surgery. 2023 Apr 4:30(1):53-56. doi: 10.48729/pjctvs.258. Epub 2023 Apr 4
[PubMed PMID: 37029946]
Level 3 (low-level) evidence
[127]
Golounina OO, Belaya ZE, Rozhinskaya LY, Pikunov MY, Markovich AA, Dzeranova LK, Marova EI, Kuznetsov NS, Fadeev VV, Melnichenko GA, Dedov II. [Survival predictors in patients with ectopic acth syndrome]. Problemy endokrinologii. 2022 Aug 15:68(6):30-42. doi: 10.14341/probl13144. Epub 2022 Aug 15
[PubMed PMID: 36689709]
[128]
Buffolo F, Tetti M, Mulatero P, Monticone S. Aldosterone as a Mediator of Cardiovascular Damage. Hypertension (Dallas, Tex. : 1979). 2022 Sep:79(9):1899-1911. doi: 10.1161/HYPERTENSIONAHA.122.17964. Epub 2022 Jun 29
[PubMed PMID: 35766038]
[129]
Mandal C, Dutta PK. Unique Case of Cardiomyopathy Secondary to Adrenal Adenoma (Primary-Aldosteronism). The Journal of the Association of Physicians of India. 2023 Jan:71(1):1
[PubMed PMID: 37116014]
Level 3 (low-level) evidence
[130]
Lee HW, Kim YJ, Jin HY, Lee KA. Primary aldosteronism presenting as embolic myocardial infarction. Neuro endocrinology letters. 2022 Sep 16:43(3):140-144
[PubMed PMID: 36179724]
Level 3 (low-level) evidence
[131]
Nguyen V, Tu TM, Mamauag MJB, Lai J, Saffari SE, Aw TC, Ong L, Foo RSY, Chai SC, Fones S, Zhang M, Puar TH. Primary Aldosteronism More Prevalent in Patients With Cardioembolic Stroke and Atrial Fibrillation. Frontiers in endocrinology. 2022:13():869980. doi: 10.3389/fendo.2022.869980. Epub 2022 Apr 19
[PubMed PMID: 35518929]
[132]
Sakaguchi S, Okamoto R, Inoue C, Akao M, Kamemura K, Kurihara I, Takeda Y, Ohno Y, Inagaki N, Rakugi H, Katabami T, Tsuiki M, Tanabe A, Tamura K, Fujita S, Yano Y, Dohi K, JRAS investigators, Naruse M. Associated factors and effects of comorbid atrial fibrillation in hypertensive patients due to primary aldosteronism. Journal of human hypertension. 2023 Sep:37(9):757-766. doi: 10.1038/s41371-022-00753-2. Epub 2022 Sep 24
[PubMed PMID: 36153382]
[133]
Zhou F, Wu T, Wang W, Cheng W, Wan S, Tian H, Chen T, Sun J, Ren Y. CMR-Verified Myocardial Fibrosis Is Associated With Subclinical Diastolic Dysfunction in Primary Aldosteronism Patients. Frontiers in endocrinology. 2021:12():672557. doi: 10.3389/fendo.2021.672557. Epub 2021 May 14
[PubMed PMID: 34054733]
[134]
Lin YH, Wu XM, Lee HH, Lee JK, Liu YC, Chang HW, Lin CY, Wu VC, Chueh SC, Lin LC, Lo MT, Ho YL, Wu KD, TAIPAI Study Group. Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. Journal of hypertension. 2012 Aug:30(8):1606-13. doi: 10.1097/HJH.0b013e3283550f93. Epub
[PubMed PMID: 22688266]
[135]
Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology. 2006 Dec 5:48(11):2293-300
[PubMed PMID: 17161262]
[136]
Küpers EM, Amar L, Raynaud A, Plouin PF, Steichen O. A clinical prediction score to diagnose unilateral primary aldosteronism. The Journal of clinical endocrinology and metabolism. 2012 Oct:97(10):3530-7. doi: 10.1210/jc.2012-1917. Epub 2012 Aug 23
[PubMed PMID: 22918872]
[137]
Chen PT, Li PY, Liu KL, Wu VC, Lin YH, Chueh JS, Chen CM, Chang CC, TAIPAI Study Group. Machine Learning Model with Computed Tomography Radiomics and Clinicobiochemical Characteristics Predict the Subtypes of Patients with Primary Aldosteronism. Academic radiology. 2023 Dec 1:():. pii: S1076-6332(23)00549-4. doi: 10.1016/j.acra.2023.10.015. Epub 2023 Dec 1
[PubMed PMID: 38042624]
[138]
Mansour N, Mittermeier A, Walter R, Schachtner B, Rudolph J, Erber B, Schmidt VF, Heinrich D, Bruedgam D, Tschaidse L, Nowotny H, Bidlingmaier M, Kunz SL, Adolf C, Ricke J, Reincke M, Reisch N, Wildgruber M, Ingrisch M. Integration of clinical parameters and CT-based radiomics improves machine learning assisted subtyping of primary hyperaldosteronism. Frontiers in endocrinology. 2023:14():1244342. doi: 10.3389/fendo.2023.1244342. Epub 2023 Aug 24
[PubMed PMID: 37693351]
[139]
Karashima S, Kawakami M, Nambo H, Kometani M, Kurihara I, Ichijo T, Katabami T, Tsuiki M, Wada N, Oki K, Ogawa Y, Okamoto R, Tamura K, Inagaki N, Yoshimoto T, Kobayashi H, Kakutani M, Fujita M, Izawa S, Suwa T, Kamemura K, Yamada M, Tanabe A, Naruse M, Yoneda T, JPAS/JRAS Study Group. A hyperaldosteronism subtypes predictive model using ensemble learning. Scientific reports. 2023 Feb 21:13(1):3043. doi: 10.1038/s41598-023-29653-2. Epub 2023 Feb 21
[PubMed PMID: 36810868]
[140]
Shi S, Tian Y, Ren Y, Li Q, Li L, Yu M, Wang J, Gao L, Xu S. A new machine learning-based prediction model for subtype diagnosis in primary aldosteronism. Frontiers in endocrinology. 2022:13():1005934. doi: 10.3389/fendo.2022.1005934. Epub 2022 Nov 23
[PubMed PMID: 36506080]
[141]
Constantinescu G, Schulze M, Peitzsch M, Hofmockel T, Scholl UI, Williams TA, Lenders JWM, Eisenhofer G. Integration of artificial intelligence and plasma steroidomics with laboratory information management systems: application to primary aldosteronism. Clinical chemistry and laboratory medicine. 2022 Nov 25:60(12):1929-1937. doi: 10.1515/cclm-2022-0470. Epub 2022 Jul 18
[PubMed PMID: 35851438]
[142]
Sam D, Kline GA, So B, Hundemer GL, Pasieka JL, Harvey A, Chin A, Przybojewski SJ, Caughlin CE, Leung AA. External Validation of Clinical Prediction Models in Unilateral Primary Aldosteronism. American journal of hypertension. 2022 Apr 2:35(4):365-373. doi: 10.1093/ajh/hpab195. Epub
[PubMed PMID: 34958097]
Level 1 (high-level) evidence